Literature DB >> 27676398

The Relationship Between Calciotropic Hormones, IGF-1, and Bone Mass Across Pubertal Stages.

Maria Matar1, Laila Al-Shaar1, Joyce Maalouf1, Mona Nabulsi1, Asma Arabi1, Mahmoud Choucair1, Hani Tamim1, Ghada El-Hajj Fuleihan1.   

Abstract

BACKGROUND: Little is known about the changes in calciotropic hormones during puberty and their relationship to bone mass during this critical period for skeletal accretion.
OBJECTIVES: Investigate changes in calciotropic hormones, IGF-1, body composition, and their associations with bone metabolism in adolescents.
METHODS: Post hoc analyses were performed from data on 335 healthy school children, ages 10-17 years, with hypovitaminosis D who participated in a vitamin D randomized controlled trial. Baseline serum biochemistries; hormonal studies; densitometry at the spine, hip, and total body; and body composition were used. ANOVA and regression analyses were implemented to evaluate changes in variables of interest across pubertal stages, within and between genders.
RESULTS: Bone mass and body composition parameters increased substantially across Tanner stages in both genders. Serum calcium, 1,25-dihydroxyvitamin D, and 25-hydroxyvitamin D levels did not vary by Tanner stages in both genders. Conversely, serum phosphorus, alkaline phosphatase, IGF-1, PTH, and osteocalcin peaked for the most part at Tanner stage II in girls and stage III in boys. 1,25-Dihydroxyvitamin D correlations with bone mass were not consistent, whereas IGF-1 was the most robust correlate of bone mass at several skeletal sites in early Tanner stages in both genders (R = 0.3-0.6).
CONCLUSION: Serum phosphorus, alkaline phosphatase, IGF-1, PTH, and osteocalcin, but not calcium or 1,25-dihydroxyvitamin D, increased significantly in early puberty, with gender difference except for PTH, peaking earlier in girls than in boys. IGF-1 is a robust predictor of bone mass, an effect mediated in large part by increments in lean mass.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27676398     DOI: 10.1210/jc.2016-3071

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

Review 1.  Insulin-like growth factors: actions on the skeleton.

Authors:  Shoshana Yakar; Haim Werner; Clifford J Rosen
Journal:  J Mol Endocrinol       Date:  2018-04-06       Impact factor: 5.098

Review 2.  Potential applications for rhIGF-I: Bone disease and IGFI.

Authors:  Marisol Bahamonde; Madhusmita Misra
Journal:  Growth Horm IGF Res       Date:  2020-03-23       Impact factor: 2.372

3.  Effects of Vitamin D Supplementation on IGF-1 and Calcitriol: A Randomized-Controlled Trial.

Authors:  Christian Trummer; Verena Schwetz; Marlene Pandis; Martin R Grübler; Nicolas Verheyen; Martin Gaksch; Armin Zittermann; Winfried März; Felix Aberer; Angelika Lang; Claudia Friedl; Andreas Tomaschitz; Barbara Obermayer-Pietsch; Thomas R Pieber; Stefan Pilz; Gerlies Treiber
Journal:  Nutrients       Date:  2017-06-17       Impact factor: 5.717

Review 4.  Non-alcoholic fatty liver disease connections with fat-free tissues: A focus on bone and skeletal muscle.

Authors:  Eleonora Poggiogalle; Lorenzo Maria Donini; Andrea Lenzi; Claudio Chiesa; Lucia Pacifico
Journal:  World J Gastroenterol       Date:  2017-03-14       Impact factor: 5.742

5.  Association of Serum Total Osteocalcin Concentrations With Endogenous Glucocorticoids and Insulin Sensitivity Markers in 12-Year-Old Children: A Cross-Sectional Study.

Authors:  Satu Seppä; Sirpa Tenhola; Raimo Voutilainen
Journal:  Front Endocrinol (Lausanne)       Date:  2019-11-19       Impact factor: 5.555

6.  Anatase and Rutile TiO2 Nanoparticles Lead Effective Bone Damage in Young Rat Model via the IGF-1 Signaling Pathway.

Authors:  Wenshu Cheng; Xinyue Xu; Yuanyuan Lang; Zugen Cheng; Mohammad Rizwan; Xiaomin Tang; Lixin Xie; Yanling Liu; Hengyi Xu; Yang Liu
Journal:  Int J Nanomedicine       Date:  2021-10-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.